ResMed Partners with Verily For Sleep Apnea Initiative
The two companies will combine technology resources to identify and reach untreated sleep apnea sufferers.
- By Leila McNeill
- Jul 11, 2018
ResMed and Verily Life Sciences LLC (San Diego and San Francisco, Calif.) have entered into a joint venture to help identify, diagnose and treat sleep apnea in undiagnosed individuals.
Sleep apnea affects an estimated 54 million Americans a year, but “The vast majority of people with sleep apnea don’t realize they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks,” Carlos Nunez, the chief medical officer at ResMed, noted in a public statement.
ResMed will combine its knowledge of sleep-disordered breathing conditions, such as obstructive sleep apnea, with Verily’s advanced health data analytics technologies to study the health and financial impact of undiagnosed and untreated sleep apnea. Data collection and analytics will enable the partners to develop software solutions for healthcare providers to identify, diagnose and subsequently treat sleep apnea more efficiently.
"By better identifying at-risk individuals as well as generating real-world evidence regarding the value and effectiveness of treatment, this collaboration has the potential to improve outcomes for millions of people living with sleep apnea, and potentially other related conditions," explained Jessica Mega, M.D., M.P.H., chief medical and scientific officer at Verily.
The venture between the two companies will operate independently from ResMed and Verily.
Leila McNeill is the Associate Editor of HME Business and Mobility Management magazines. She can be reached at LMcNeill@1105media.com.